Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Imunon, Inc. (IMNN)

Imunon to sell ThermoDox to VoxelDox; deal contingent on $2.5 million financing

Neutral Impact 3 of 5 m&a Written later

On October 20, 2026, Imunon agreed to sell its ThermoDox assets to VoxelDox Therapeutics. The deal closes only if VoxelDox raises at least $2.5 million; otherwise Imunon receives no consideration, and if it closes, Imunon would receive a 4.76% equity stake, up to $16.5 million in milestone payments, and royalties on net sales. The company describes ThermoDox as a legacy asset that has been fully written off and says it will keep its resources focused on the IMNN-001 Phase 3 program.

Key points

  • Closing depends on VoxelDox raising at least $2.5 million; no consideration is paid if it does not.
  • If the deal closes, Imunon receives 4.76% of VoxelDox's fully diluted capitalization.
  • Imunon could receive up to $16.5 million in milestone payments and royalties on annual net sales; milestones and royalties are cut by 50% if the transferred vials are determined to be unusable.
  • Imunon may appoint one of VoxelDox's five directors and one non-voting observer until VoxelDox completes a qualified equity financing.

The filing

CompanyImunon, Inc. (IMNN)
Form8-K, current report
Filed with the SECOct 21, 2026, 8:15 AM ET
Accession number0001493152-26-047850

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.